{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"12"}],"units":"Participants"}],"description":"Frequency (%) of patients with Partial Response (PR) or Complete Response (CR) using the RECIST criteria by study part and dose level","groups":[{"description":"Patients receive oral sorafenib 105 mg/m\\^2 every 12 hours.","id":"OG000","title":"Part A: Refractory Solid Tumors: BAY 43-9006 105 mg/m^2"},{"description":"Patients receive oral sorafenib 130 mg/m\\^2 every 12 hours.","id":"OG001","title":"Part A: Refractory Solid Tumors: BAY 43-9006 130 mg/m^2"},{"description":"Patients receive oral sorafenib 150 mg/m\\^2 every 12 hours.","id":"OG002","title":"Part A: Refractory Solid Tumors: BAY 43-9006 150 mg/m^2"},{"description":"Patients receive oral sorafenib 200 mg/m\\^2 every 12 hours.","id":"OG003","title":"Part A: Refractory Solid Tumors: BAY 43-9006 200 mg/m^2"},{"description":"Patients receive oral sorafenib 250 mg/m\\^2 every 12 hours.","id":"OG004","title":"Part A: Refractory Solid Tumors: BAY 43-9006 250 mg/m^2"},{"description":"Patients receive oral sorafenib 150 mg/m\\^2 every 12 hours.","id":"OG005","title":"Part B: Refractory Leukemia: BAY 43-9006 150 mg/m^2"},{"description":"Patients receive oral sorafenib 200 mg/m\\^2 every 12 hours.","id":"OG006","title":"Part B: Refractory Leukemia: BAY 43-9006 200 mg/m^2"},{"description":"Patients receive oral sorafenib 150 mg/m\\^2 every 12 hours.","id":"OG007","title":"Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2"},{"description":"Patients receive oral sorafenib 200 mg/m\\^2 every 12 hours.","id":"OG008","title":"PK Cohort Expanded: BAY 43-9006 200 mg/m^2"}],"paramType":"NUMBER","populationDescription":"There were 55 evaluable patients","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Number of Patients Who Respond Using RECIST Criteria","type":"SECONDARY","unitOfMeasure":"participants"}